US-based nutraceutical drugs supplier ScripsAmerica has signed a Letter of Intent (LOI) to acquire global pharmaceutical packaging company Marlex Pharmaceuticals.
Marlex Pharmaceuticals’ new Castle, Delaware facility consists of 12,000ft² of temperature-controlled space for pharmaceutical packaging, contract packaging and private labeling.
The facility is in accordance with the Food and Drug Administration (FDA), Drug Enforcement Administration (DEA) and the state board of pharmacy.
The acquisition will provide ScripsAmerica opportunities to secure government contracts due to Marlex’s relationships and is expected to have a positive impact on both companies. It will also add 10% to 15% to the company’s gross profit margin.
Following the acquisition, ScripsAmerica will increase its processing capacity and will continue to seek strategic acquisition partners in markets including the prescription, generic drug and OTC.